(HealthDay News) — High coffee intake is associated with longer prostate cancer-specific survival (PCSS) for certain subgroups of patients, including those with the CYP1A2 AA genotype, according to a study published in European Urology Oncology.
Justin R. Gregg, MD, from the University of Texas MD Anderson Cancer Center in Houston, and colleagues examined the associations between coffee intake, caffeine metabolism genotype, and survival using data from the PRACTICAL Consortium database for 5727 men with prostate cancer.
Cases had data available for the CYP1A2 163C>A rs762551 single-nucleotide variant associated with caffeine metabolism, coffee consumption, and follow-up of more than 6 months.
Overall, there was no significant association between coffee intake and PCSS (hazard ratio [HR], 0.85; 95% CI, 0.68-1.08; P =.18) or overall survival (HR, 0.90; 95% CI, 0.77-1.07; P =.24). Similarly, there were no significant associations between coffee intake and overall survival in any of the subgroups.
However, among patients with clinically localized disease, high coffee intake was associated with significantly longer PCSS (HR, 0.66; 95% CI, 0.44-0.98; P =.040). High coffee intake was also associated with significantly longer PCSS among patients with the CYP1A2 AA genotype (HR, 0.67; 95% CI, 0.49-0.93; P =.017) but not the AC/CC genotype (P = .8).
“Future work is needed to replicate these findings, to determine the specific populations (such as those with a fast caffeine metabolism genotype) in which coffee-based interventions or coffee intake ‘prescriptions’ could be beneficial, and to define the mechanisms through which coffee- and caffeine-related metabolites impact prostate cancer progression,” the authors wrote.
One author disclosed financial ties to Bayer.